McKesson Co. (NYSE:MCK) Expected to Earn Q1 2025 Earnings of $7.16 Per Share

McKesson Co. (NYSE:MCKFree Report) – Analysts at Zacks Research increased their Q1 2025 earnings per share estimates for McKesson in a research note issued on Tuesday, May 28th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will post earnings of $7.16 per share for the quarter, up from their prior estimate of $6.96. The consensus estimate for McKesson’s current full-year earnings is $31.57 per share. Zacks Research also issued estimates for McKesson’s Q2 2025 earnings at $7.58 EPS, Q3 2025 earnings at $8.14 EPS, FY2025 earnings at $31.34 EPS, Q1 2026 earnings at $7.64 EPS, Q2 2026 earnings at $8.10 EPS and FY2027 earnings at $40.14 EPS.

McKesson (NYSE:MCKGet Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported $6.18 earnings per share for the quarter, missing the consensus estimate of $6.34 by ($0.16). The firm had revenue of $76.36 billion during the quarter, compared to analyst estimates of $79.32 billion. McKesson had a net margin of 0.97% and a negative return on equity of 245.88%. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the prior year, the firm earned $7.19 earnings per share.

Several other research firms have also weighed in on MCK. Deutsche Bank Aktiengesellschaft reduced their target price on shares of McKesson from $547.00 to $545.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Robert W. Baird boosted their price objective on McKesson from $603.00 to $671.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 8th. Wells Fargo & Company increased their target price on McKesson from $502.00 to $551.00 and gave the company an “equal weight” rating in a research note on Thursday, May 9th. Barclays boosted their price target on McKesson from $571.00 to $596.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 8th. Finally, TD Cowen increased their price objective on shares of McKesson from $563.00 to $652.00 and gave the company a “buy” rating in a research report on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $571.47.

Read Our Latest Stock Analysis on MCK

McKesson Stock Up 0.4 %

MCK opened at $561.11 on Thursday. McKesson has a 52-week low of $373.28 and a 52-week high of $566.16. The company has a 50 day moving average of $540.65 and a two-hundred day moving average of $505.21. The company has a market cap of $72.94 billion, a P/E ratio of 25.07, a P/E/G ratio of 1.28 and a beta of 0.45.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Monday, June 3rd will be issued a $0.62 dividend. The ex-dividend date of this dividend is Monday, June 3rd. This represents a $2.48 annualized dividend and a yield of 0.44%. McKesson’s dividend payout ratio is presently 11.08%.

Insider Buying and Selling at McKesson

In other news, EVP Leann B. Smith sold 704 shares of the business’s stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $558.09, for a total value of $392,895.36. Following the completion of the sale, the executive vice president now owns 2,215 shares of the company’s stock, valued at approximately $1,236,169.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Leann B. Smith sold 704 shares of McKesson stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $558.09, for a total value of $392,895.36. Following the completion of the transaction, the executive vice president now owns 2,215 shares in the company, valued at approximately $1,236,169.35. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Britt J. Vitalone sold 12,752 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $558.09, for a total value of $7,116,763.68. Following the completion of the sale, the chief financial officer now owns 14,028 shares of the company’s stock, valued at $7,828,886.52. The disclosure for this sale can be found here. Insiders have sold 19,219 shares of company stock worth $10,608,252 in the last ninety days. 0.21% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Cambridge Trust Co. boosted its stake in McKesson by 386.4% in the first quarter. Cambridge Trust Co. now owns 107 shares of the company’s stock valued at $57,000 after acquiring an additional 85 shares during the period. Soltis Investment Advisors LLC boosted its position in McKesson by 1.2% during the 1st quarter. Soltis Investment Advisors LLC now owns 14,136 shares of the company’s stock valued at $7,589,000 after purchasing an additional 174 shares during the period. Boston Partners grew its stake in McKesson by 4.1% during the 1st quarter. Boston Partners now owns 1,183,829 shares of the company’s stock worth $635,763,000 after buying an additional 47,140 shares during the last quarter. Cetera Advisors LLC increased its position in McKesson by 343.2% in the first quarter. Cetera Advisors LLC now owns 10,516 shares of the company’s stock worth $5,645,000 after buying an additional 8,143 shares during the period. Finally, Cetera Investment Advisers lifted its stake in McKesson by 144.5% in the first quarter. Cetera Investment Advisers now owns 37,197 shares of the company’s stock valued at $19,969,000 after buying an additional 21,981 shares during the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Company Profile

(Get Free Report)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

See Also

Earnings History and Estimates for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.